When opposed to SGLT2i, GLP-1 RAs appear to have fewer direct renoprotective advantages, particularly in non-diabetic CKD populations, despite their strong glycemic control, weight loss and small reductions in albuminuria. The gene discussed is GLP1R; the disease is chronic kidney disease.